Elocon contains mometasone furoate as its active ingredient. It is a potent, prescription-only topical corticosteroid formulated as a 0.1 % cream or ointment supplied in a 5 g tube. In Hong Kong, Elocon is regulated by the Department of Health under the Medicines and Poisons Ordinance and is approved for short-term treatment of inflammatory skin conditions.
Mometasone furoate belongs to the corticosteroid class. It binds to glucocorticoid receptors in the cytoplasm of skin cells, forming a complex that translocates to the nucleus and modulates gene transcription. This leads to:
The anti-inflammatory effect typically begins within a few hours of application, peaks after 24-48 hours, and persists for the duration of treatment. Because the drug is applied directly to the skin, systemic exposure is minimal when used as directed.
Elocon is FDA- and EMA-equivalent approved for the following dermatologic indications, also recognized by Hong Kong regulators:
It is intended for short-term use (usually up to 2 weeks) or intermittent courses, depending on the clinician’s assessment.
Current peer-reviewed literature provides limited evidence for off-label use of mometasone furoate in:
Off-label use requires medical supervision and individualized risk assessment.
Absolute contraindications
Relative contraindications
Patients with extensive skin loss, uncontrolled diabetes, or immunosuppression should discuss alternative therapies with their provider.
These effects are usually transient and subside with continued use or after discontinuation.
If signs of severe irritation, worsening rash, or systemic symptoms (e.g., unusual weight gain, facial swelling) occur, seek medical attention promptly.
Topical mometasone has minimal systemic drug-drug interactions, but clinicians should be aware of:
Patients should disclose all prescription, over-the-counter, and herbal products before starting Elocon.
This article provides educational information about Elocon and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Elocon may be used on facial skin for conditions such as seborrheic dermatitis or limited atopic dermatitis, but only under a clinician’s direction because facial skin is more susceptible to thinning and stretch-mark formation.
When applied once daily to moderate-size lesions, a 5 g tube generally provides enough medication for approximately 10-14 days. Larger affected areas or more frequent dosing will deplete the tube sooner.
Yes, short-term exposure to water does not diminish efficacy. However, avoid prolonged immersion with occlusive dressings, as this can increase absorption.
Topical corticosteroids are not typically screened for in standard anti-doping tests, but elite sport governing bodies may have specific rules regarding systemic exposure. Athletes should check their organization’s policy.
Applying a fragrance-free, non-comedogenic moisturizer after Elocon has absorbed can help reduce dryness and support skin barrier recovery.
Remove the dressing immediately, rinse the area with mild soap and water, and contact a healthcare professional. The reaction may indicate heightened steroid absorption or an allergic response.
Elocon is approved for patients 12 years and older. For younger children, a lower-potency corticosteroid is typically recommended.
If the skin is colonized with bacterial infection, clinicians often prescribe an antibiotic alongside or before the steroid to avoid worsening the infection.
In Hong Kong, discard the empty tube in regular household waste if it contains no residual medication, or return it to a pharmacy’s medication-take-back program for safe disposal.
Mometasone furoate does not typically increase sensitivity to sunlight, but irritated skin may be more vulnerable. Use sunscreen if prolonged sun exposure is anticipated.
